TEL AVIV, Israel – Use of Vaica Medical’s SimpleMed digital platform improved medication adherence in teen and young adult kidney transplant recipients, according to a study published recently in the American Journal of Kidney Disease.
The goal of the TAKE-IT study conducted by researchers at McGill University Health Center in Montreal was to find out if a program of regular coaching, review of electronically-monitored adherence and use of the SimpleMed medication management and reminder system would help young people to take their transplant medications better. Results found that participants had 66% higher adherence to anti-rejection medication.
“Now that the trial is complete and showed that using the SimpleMed electronic pillbox, in combination with coaching, helped young people adhere to a strict schedule of anti-rejection medication, I hope to be able to move this intervention into clinical practice,” said Dr. Bethany Foster, principal investigator of the TAKE-IT study and primary author of the study.
Pediatric departments at eight leading medical centers in Canada and the United States enrolled a combined 81 patients in the TAKE-IT intervention group and 88 in the control group. All participants met with a study coach every three months for 15 months. Those assigned to the TAKE-IT intervention group could choose to receive text message, email, and/or visual cue dose reminders, and reviewed adherence data from the prior three months with their coach. Those in the control group used the electronic monitor but received only general social support with no alerts or notifications. Adherence improved and was 66% higher among patients who received the intervention than among controls.
Vaica Medical has also been chosen to design the customized, medication management and adherence solution in a follow-up study, TAKE-IT TOO, in which study investigators will collaborate with the company, patients, parents and health care professionals to design a medication monitoring and adherence support system specifically for young people, adapt the TAKE-IT intervention for use in clinical practice and test the new device and intervention in a pilot trial. TAKE-IT TOO is being funded by the National Institute of Health.